UDR Declares Quarterly Dividend

DENVER--(BUSINESS WIRE)-- UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust, today announced that its Board of Directors declared a regular quarterly dividend on its common stock for the second quarter of 2021 in the amount of $0.3625 per share, payable in cash, on August 2, 2021 to UDR common stock shareholders of record as of July 12, 2021. The August 2, 2021 dividend will be the 195th consecutive quarterly dividend paid by the Company on its common stock.

UDR also announced that its Board of Directors declared a regular quarterly dividend on its Series E preferred stock for the second quarter of 2021 in the amount of $0.3925 per share. The preferred dividend is payable on August 2, 2021 to Series E preferred stock shareholders of record as of July 12, 2021.

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of March 31, 2021, UDR owned or had an ownership position in 52,617 apartment homes including 1,417 homes under development. For over 48 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005773/en/

Trent Trujillo
[email protected]
720-283-6135

Source: UDR, Inc.

You May Also Be Interested In

• Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
• HBAR Price Prediction: Hedera Joins Five Groups Pressing SEC as Remittix Earn Readies Morpho, Fluid and Maple Finance Pools
• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026